144 related articles for article (PubMed ID: 7873455)
1. Treatment of advanced breast cancer with formestane.
Murray R; Pitt P
Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
[TBL] [Abstract][Full Text] [Related]
2. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
[TBL] [Abstract][Full Text] [Related]
4. Formestane in the treatment of advanced postmenopausal breast cancer.
Possinger K; Jonat W; Höffken K
Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
[TBL] [Abstract][Full Text] [Related]
5. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Wiseman LR; Goa KL
Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
[TBL] [Abstract][Full Text] [Related]
6. Proper sequence of endocrine therapies in advanced breast cancer.
Rose C
Acta Oncol; 1996; 35 Suppl 5():44-9. PubMed ID: 9142964
[TBL] [Abstract][Full Text] [Related]
7. Severe immune thrombocytopenia during formestane treatment.
Español I; Muñíz-Díaz E; Alonso MC; Pujol-Moix N
Haematologica; 1998 Oct; 83(10):953-4. PubMed ID: 9830809
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of formestane in postmenopausal women with breast cancer.
Joseph JK; Lim AK
Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135
[TBL] [Abstract][Full Text] [Related]
9. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.
Murray R; Pitt P
Breast Cancer Res Treat; 1995 Sep; 35(3):249-53. PubMed ID: 7579495
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
Höffken K; Jonat W; Possinger K; Kölbel M; Kunz T; Wagner H; Becher R; Callies R; Friederich P; Willmanns W
J Clin Oncol; 1990 May; 8(5):875-80. PubMed ID: 2185341
[TBL] [Abstract][Full Text] [Related]
12. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
[TBL] [Abstract][Full Text] [Related]
13. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
[TBL] [Abstract][Full Text] [Related]
14. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
[TBL] [Abstract][Full Text] [Related]
15. Formestane: an effective first-line endocrine treatment for advanced breast cancer.
Zilembo N; Bajetta E; Noberasco C; Buzzoni R; Vicario G; Bono A; Laffranchi A; Biasi G; Dolci S; Bichisao E
J Cancer Res Clin Oncol; 1995; 121(6):378-82. PubMed ID: 7797604
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Lønning PE
Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
[TBL] [Abstract][Full Text] [Related]
17. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
18. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
[TBL] [Abstract][Full Text] [Related]
19. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
Wiseman LR; McTavish D
Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
[TBL] [Abstract][Full Text] [Related]
20. Formestane for advanced breast cancer in postmenopausal women.
Drug Ther Bull; 1993 Oct; 31(22):85-7. PubMed ID: 8269826
[No Abstract] [Full Text] [Related]
[Next] [New Search]